SamSearch Platform
AI-powered intelligence for the right opportunities, the right leads, and the right time.
Contract Category
13 federal contract opportunities classified as Cell Therapy.
DEPARTMENT OF HEALTH AND HUMAN SERVICES
AI Summary
The National Institutes of Health intends to award a sole-source contract for preventative maintenance and service support for seventeen ChemoMetec NC-202 instruments. This service is critical for compliance with FDA regulations in cell therapy manufacturing. Capability statements are due by August 13, 2026, at 6:00 P.…
MD
AI Summary
The NIH Clinical Center intends to award a sole-source contract for CryoStor® CS10, 100 mL bags, essential for cryopreserving cell-based therapies in clinical trials. BioLife Solutions is the sole manufacturer of this validated product, which meets FDA standards. Capability statements are due by August 13, 2026, at 6:0…
MD
DEPARTMENT OF HEALTH AND HUMAN SERVICES
AI Summary
The NIH Clinical Center intends to award a sole-source contract to Fisher Scientific for validated reagents and consumable materials essential for manufacturing FDA-regulated cell-based therapies. These materials are critical for clinical trials, and substitution would require extensive revalidation. Capability stateme…
MD
AI Summary
The NIH intends to award a sole source purchase order for five cases of G-Rex500M bioreactors from Wilson Wolf Manufacturing. These bioreactors are essential for FDA-regulated manufacturing processes in cell-based therapies. Interested sources may submit capability statements by August 7, 2026, to demonstrate their abi…
MD
AI Summary
The Department of Veterans Affairs intends to award a sole source contract to the University of Connecticut Health Center for services related to reprogrammed stem cells for osteoarthritis. This contract will span five years, and interested parties must submit capability information by 10:00am (EST) on August 6, 2026.
PA
AI Summary
The National Institutes of Health intends to award a sole-source contract for seven G-Rex500M bioreactors to Wilson Wolf Manufacturing LLC. These bioreactors are essential for the manufacture of cell-based therapies in FDA-regulated processes. Interested parties may submit capability statements by July 17, 2026, for co…
MD
DEPARTMENT OF HEALTH AND HUMAN SERVICES
AI Summary
The National Institutes of Health intends to award a sole source contract to ACROBiosystems Inc. for fifteen vials of GMP Human IL-2 Protein. This procurement is critical for FDA-regulated cell and gene therapy manufacturing, and no competitive quotations will be solicited. Interested parties may submit capability stat…
MD
AI Summary
The BioStabilization Systems (BoSS) program seeks innovative solutions to enhance the stabilization and distribution of live cell-based therapies. Interested parties must submit Solution Summaries by specified deadlines in 2026. This opportunity focuses on advancing bioprocessing technologies to improve healthcare deli…
MD
AI Summary
The Department of Veterans Affairs is seeking sources for stem cell therapy services for the period from May 18, 2026, to May 17, 2027. This opportunity is set aside for Service-Disabled Veteran-Owned Small Businesses (SDVOSBC). Interested parties should respond to this sources sought notice.
CA
AI Summary
The National Institutes of Health intends to negotiate a five-year service contract for Cytek Aurora 3 laser flow cytometers. This contract will support clinical research and cell therapeutic product development. Interested vendors may submit capability statements by April 23, 2026, for consideration.
MD
DEPARTMENT OF HEALTH AND HUMAN SERVICES
AI Summary
The Department of Health and Human Services intends to award a sole source contract to Xcell Biosciences for leasing four Avatar™ Odyssey instruments for six months. These instruments are essential for process development in cell therapy, providing precise control of cellular microenvironment conditions. Interested par…
MD
AI Summary
The Department of Health and Human Services intends to award a sole source contract to BD Biosciences for a five-year service contract involving maintenance of flow cytometers and related equipment. This acquisition is conducted under FAR Part 13 Simplified Acquisition Procedures, allowing for a single-source procureme…
MD
DEPARTMENT OF HEALTH AND HUMAN SERVICES
AI Summary
The National Institutes of Health intends to award a sole source contract for the MaxCyte ExPERT GTx Electroporation Device and associated installation and operational qualification services. This acquisition is necessary to maintain compliance with cGMP standards in cell-based therapy manufacturing. Interested parties…
MD
Common questions about finding and winning Cell Therapy government contracts.